LEADERS IN ONCOLOGIC INTERVENTIONS

ECIO 2020
European Conference on Interventional Oncology
April 26-29
Nice, France

www.ecio.org
Interventional oncology is continuously growing, frequently branching into new areas and making exciting progress. Staying up-to-date on all of these constant changes can be challenging; in order to facilitate conversation and push the envelope for innovation even further, the European Conference on Interventional Oncology (ECIO) offers a wide range of oncological specialists a comprehensive forum for education, networking and exchange.

Since its first meeting in 2008, ECIO has evolved from a small, yet significant biennial meeting of IRs into the leading annual congress in the field of interventional oncology, bringing a multidisciplinary group of nearly 1,500 healthcare professionals from 65 countries together to learn and discuss the latest topics and future advancements in IO. With the upcoming congress in Nice, France, ECIO hopes to expand on this success, creating a space for professionals across an even broader range of disciplines to meet and work toward innovations in cancer care.

The Scientific Programme Committee has been working diligently to create an expansive scientific programme covering a broad spectrum of relevant topics for all those working in the oncologic field. It will once again explore a plethora of clinical subjects, from well-established therapies, such as local ablation for HCC, to newer clinical areas, such as immunotherapy and advances in nuclear medicine.

Focus on curative treatments

The ECIO 2020 programme also recognises the expanding role of minimally invasive treatments in tackling cancer head-on. As in previous years, Clinical Focus Sessions examining HCC procedures, such as Hepatocarcinoma: from classification to treatment, will provide an excellent model for how interventional oncology can achieve quality outcomes in cancer care. Other sessions, such as Nuclear medicine and interventional oncology – present and future, will explore new data and expert advice on some of the field’s latest and most promising treatment possibilities which continue to enhance the overall impact of interventional oncology for patients.

Another exciting aspect of the ECIO 2020 programme is a Clinical Focus Session titled Upcoming European Research, which will provide the opportunity for young researchers

Committees

Scientific Programme Committee

Alban Denys (CH), Chairperson
Philippe L. Pereira (DE), Deputy Chairperson
Dirk Arnold (DE)
Tiago Bilhim (PT)
David J. Breen (UK)
Patrick Chevallier (FR)
Thierry de Baère (FR)
Afshin Gangi (FR)
Thomas J. Kroencke (DE)
Martijn R. Meijerink (NL)
Franco Orsi (IT)
Lambros Tselikas (FR)

Local Host Committee

Patrick Chevallier (Nice), Chairperson
Sophie Aufort (Montpellier)
Christophe Cassinotto (Montpellier)
Pascal Chabrot (Clerrmont-Ferrand)
Audrey Fohlen (Caen)
Boris Guiu (Montpellier)
Fabrice Lame (Nice)
Maxime Ronot (Clichy)
Vania Tacher (Créteil)
Vincent Vidal (Marseille)
to present their latest work, delving into timely topics such as intratumoral immunotherapy, cryo-priming in immuno-response and endothelial antibody capture. This session will help us look forward, both examining the implications of current developments and the future possibilities of the field at large.

Expanding opportunities to share research

As a new feature, ECIO 2020 allowed attendees to submit abstracts in the form of a case report – in addition to scientific abstracts and educational abstracts – bringing the submission types in line with the CIRSE annual congress. All accepted case reports, as well as educational abstracts and select scientific abstracts, will be available for public viewing at the congress, providing authors the opportunity to receive comments directly from the onsite workstations. We hope that this will give a diverse group of IRs and oncology specialists the opportunity to share their research and receive valuable feedback.

Our beautiful host city

Located on the French Rivera, the picturesque city of Nice provides an ideal backdrop for ECIO 2020. As a top location for both business and leisure, Nice is connected to France's second largest airport, Nice Côte d'Azur, linking the city with direct service to 90 cities in 40 countries. As the congress will be hosted at the award-winning Acropolis Exhibition Centre, it can be conveniently accessed from the city centre by a major tramline.

In collaboration with our travel partner Kuoni DMC, we have reserved the most ideally situated and comfortable congress hotels, ensuring a pleasurable stay throughout your time in this stunning and dynamic city.

We look forward to welcoming you to Nice!
On se retrouve à Nice!
European Conference on Interventional Oncology

Preliminary Programme

Preliminary Faculty

Subject to change

Abadal J.M. (Madrid/ES)
Adam A. (London/UK)
Adema G. (Nijmegen/NL)
Akhan O. (Ankara/TR)
Arai Y. (Tokyo/JP)
Arnold D. (Hamburg/DE)
Ayuso C. (Barcelona/ES)
Bale R. (Innsbruck/AT)
Bargellini I. (Pisa/IT)
Barnacle A.M. (London/UK)
Bauones S. (Riad/SA)
Bell J. (Manchester/UK)
Bex A. (Amsterdam/NL)
Bilhim T. (Lisbon/PT)
Breen D.J. (Southampton/UK)
Bridgewater J. (London/UK)
Brody J. (New York, NY/US)
Brountzos E. (Athens/GR)
Bryant T. (Southampton/UK)
Burrel M. (Barcelona/ES)
Buy X. (Bordeaux/FR)
Callstrom M.R. (Rochester, MN/US)
Cazzato R.L. (Strasbourg/FR)
Cervelli R. (Pisa/IT)
Champiat S. (Villejuif/FR)
Chapiro J. (New Haven, CT/US)
Chevallier P. (Nice/FR)
Coimbra E. (Lisbon/PT)
Correas J.-M. (Paris/FR)
Crocetti L. (Pisa/IT)
Curigliano G. (Milan/IT)
de Baère T. (Villejuif/FR)
de Boo D.W. (New Lambton Heights/AU)
de Jong K. (Groningen/NL)
Denys A. (Lausanne/CH)
Deschamps F. (Villejuif/FR)
Digklia A. (Lausanne/CH)
Douane F. (Nantes/FR)
Doyen J. (Nice/FR)
Dudderidge T. (Southampton/UK)
Duran R. (Lausanne/CH)
Filippiadis D.K. (Athens/GR)
Fohlen A. (Caen/FR)
Fuchs M. (Munich/DE)
Füttner J.J. (Nijmegen/NL)
Gahide G. (Montreal/CA)
Gambardella V. (Valencia/ES)
Gangi A. (Strasbourg/FR)
Garcia-Monaco R. (Buenos Aires/AR)
Garin E. (Rennes/FR)
Gannon J. (Strasbourg/FR)
Gaubert J.Y. (Marseille/FR)
Goldberg N. (Jerusalem/IL)
Golffier R. (Bologna/IT)
Grasso R.F. (Rome/IT)
Graumann O. (Odense/DK)
Guiu B. (Montpellier/FR)
Guthrie A. (Leeds/UK)
Haanen J. (Amsterdam/NL)
Haen S. (Tübingen/DE)
Hakimé A. (Villejuif/FR)
Helmergerber T.K. (Munich/DE)
Heymann S. (Strasbourg/FR)
Hocquelet A. (Lausanne/CH)
Hoffmann R.-T. (Dresden/DE)
Iannielli A. (Nice/FR)
Iezzi R. (Rome/IT)
Ikeda M. (Tokyo/JP)
Ilkan H. (Munich/DE)
Ilyas S. (London/UK)
Jakobs T.F. (Munich/DE)
Jayankura M. (Brussels/BE)
Jennings J.W. (St. Louis, MO/US)
Jenniskens S. (Nijmegen/NL)
Kazemier G. (Amsterdam/NL)
Kelekis A.D. (Athens/GR)
Kenny L.M. (Brisbane/AU)
King A. (Southampton/UK)
Kroencke T.J. (Augsburg/DE)
Kurup A.N. (Rochester, MN/US)
Laasch H.-U. (Manchester/UK)
Lam M.G.E.H. (Utrecht/NL)
Lee F.T. (Madison, WI/US)
Lencioni R. (Pisa/IT)
Luz J.H. (Lisbon/PT)
Mahnken A.H. (Marburg/DE)
Malagari K. (Athens/GR)
Maleux G. (Leuven/BE)
Martens U. (Heilbronn/DE)
Mauri G. (Milan/IT)
Meijerink M.R. (Amsterdam/NL)
Muglia R. (Rozzano/IT)
Narayanan G. (Miami, FL/US)
Nielsen T.K. (Aarhus/DK)
Orsi F. (Milan/IT)
Ottensmeier C. (Southampton/UK)
Palussiere J. (Bordeaux/FR)
Park S.J. (Incheon/KR)
Pereira P.L. (Heilbronn/DE)
Pinto Marques H. (Lisbon/PT)
Poretti D. (Rozzano/IT)
Rao P.P. (Colmar/FR)
Reimer P. (Karlsruhe/DE)
Ricke J. (Munich/DE)
Ronot M. (Clichy/FR)
Salen R. (Chicago, IL/US)
Sangro B. (Pamplona/ES)
Scheffer N. (Lausanne/CH)
Scheffer H.J. (Amsterdam/NL)
Schmit G.D. (Rochester, MN/US)
Soror O. (Bondy/FR)
Sofocleous C.T. (New York, NY/US)
Solbiati L. (Rozzano/IT)
Solomon S.B. (New York, NY/US)
Sommer C.-M. (Heidelberg/DE)
Sone M. (Tokyo/JP)
Stedman B. (Southampton/UK)
Suh R.D. (Los Angeles, CA/US)
Tacher V. (Crestel/FR)
Tanaka T. (Kashiwara/JP)
Tselikas L. (Villejuif/FR)
Tsoumakidou G. (Lausanne/CH)
Urbano J. (Madrid/ES)
Válek V. (Brno/CZ)
van Lienden K.P. (Amsterdam/NL)
van Strijen M.J.L. (Nieuwegein/NL)
Varano G.M. (Milan/IT)
Vauthey J.-N. (Houston, TX/US)
Wacker F. (Hannover/DE)
Wah T.M. (Leeds/UK)
Wood B.J. (Bethesda, MD/US)
Woodward E. (Manchester/UK)
Yamakado K. (Osaka/JP)
Katerina Malagari is a graduate from the National and Kapodistrian University of Athens Medical School. After achieving her radiology board certification in 1990, she went to Birmingham, Alabama, for a fellowship in chest imaging, followed by a two-year fellowship in interventional radiology at Athens University’s Department of Radiology. Prof. Malagari finished her PhD in 1992 and obtained the EBIR diploma in 2010.

In 2007, Prof. Malagari became the president of the European Society of Thoracic Imaging. She is a member of the editorial board of five international journals and has been awarded “best published study of the year” on five separate occasions. Another one of her notable accomplishments was being part of the team that first introduced EVAR in Greece. She was awarded the title of Distinguished CIRSE Fellow in 2015.

Katerina Malagari has written eleven Greek and five international books. Since 2007, her research work has focused on interventional radiology, chest and interventional oncology. She has written 98 scopus-indexed articles, including 30 pieces on chemoembolisation and bland embolisation of liver tumors, three articles on prostatic embolisation, eight on non-vascular liver interventions, three on pharmacokinetics, one on an animal study, 16 on chest interventions, three on EVAR, and 34 on diagnostic radiology, with an author index of 27 and 3,261 citations (3,162 without self citations).

In total, 30 of Prof. Malagari’s articles have been featured in Greek journals. She has supervised 46 postgraduate MSCs and nine PhDs and participated in nine multicenter projects with European countries and the US.

Prof. Malagari has shared her experience around the world through her prolific didactic activity including 103 invited lectures in Greece and 114 lectures at international congresses.
CIRSE supports the “Collaborating Against Cancer” initiative with €100,000!

The ECIO initiative allows interventional radiologists with a full registration for ECIO 2020 in Nice to invite their non-radiologist colleague to the conference free of charge.

The first 100 referring physicians to sign up will receive free registration and up to €1,000 in travel support.

“This programme allowed my oncologist colleague to gain more awareness about the developments and possibilities in interventional oncology.”

Christiaan van der Leij | Interventional Radiologist

“This initiative is very important because we can get the newest insights and background information necessary to counsel patients as optimally as possible.”

Judith de Vos-Geelen | Oncologist

For further information and registration visit www.ecio.org
10 reasons why you can’t miss ECIO 2020

1. Offering a strong focus
ECIO offers a uniquely focused look at the fourth pillar of cancer care, providing a platform for experts in interventional radiology and other medical specialties to come together and discuss minimally invasive IO treatments for a wide range of malignancies.

2. Creating solid knowledge
With 18 clinical and technical focus sessions, ECIO 2020 attendees will have the opportunity to widen their knowledge on every aspect of IO treatment, receiving pointers on the nitty-gritty of various procedures, tips and tricks on tools and materials, and learning from their colleague’s experience in case-based discussions.

3. Providing hands-on experience
For those itching to try out their newly acquired knowledge, ECIO 2020 will offer numerous opportunities to gain practical experience in device trainings sessions. Topics will include image guidance, microwave ablation, RFA, and cryo-and laser ablation.

4. Exploring immuno-oncology
In IO 4 IO, a dedicated session on immuno-oncology in IO, a panel of experts will examine the ideal drugs and routes for immunotherapy, and will scrutinise the results that have been gained in this relatively new field of interventional oncology.

5. Examining curative treatments
Recognising the expanding role of minimally invasive treatments in curative cancer treatments, a Clinical Focus Session will delve into curative treatment in oligometastatic bone disease, examining the ideal candidate for local treatment, the right tools, avoiding complications and potential challenges in follow-up.

6. Sharing research
As the leading platform for scientific exchange in interventional oncology, ECIO will offer a keen look at the available data, with numerous clinical focus sessions examining the latest study and trial results. In the dedicated session on upcoming European research, attendees will get a first glimpse at where IO research is heading on the continent in the years to come.

7. Offering a variety of session formats
ECIO offers a variety of formats, each geared at optimally encouraging learning and knowledge exchange. Session types include Clinical and Technical Focus Sessions, Basic Courses, and Free Paper Sessions, as well as a Video Learning Session.

8. Stimulating interaction
ECIO attendees are strongly encouraged to engage in the programme by asking the faculty questions in person or via the app for a lively debate at the end of each session.

9. Creating strong allies
The Collaborating against Cancer Initiative (CACI) allows interventional radiologists attending ECIO to bring a colleague from their tumour board to the congress free of charge. It is the perfect opportunity for IOs to show their colleagues what interventional oncology has to offer, creating strong allies to advance minimally invasive approaches in the fight against cancer.

10. Showing you all that’s new
Boasting the world’s largest IO exhibition, ECIO offers a unique look at everything device and materials manufacturers have to offer and a great opportunity to liaise with the industry through dedicated learning centres.
Tuesday, April 28

08:00
Satellite Symposium

09:00
CF 1501
Renal cancer ablation: moving forward

CF 1502
Upcoming European research

10:00
Break

11:00
CF 1601
Challenges in IO

CF 1602
Palliation in oncology

TA-HDT 5
Tumour ablation: Cryo- and laser

12:00
Lunch break

13:00
Satellite Symposium

14:00
Satellite Symposium

15:00
Break

15:30
CF 1801
MSK palliation: the pelvic bone

VL 1802
How I do it

TA-HDT 6
Tumour ablation: Image guidance

16:30
Break

17:00
CF 1901
Imaging and clinical follow-up

FP 1902
Free Paper Session 2

BC 1903
Basic Course: Genitourinary

18:00
Satellite Symposium

Wednesday, April 29

08:00
Satellite Symposium

09:00
TF 2101
Tips and tricks: case-based discussion

CF 2102
Different ways of killing cancer – and why we need all of them

10:00
Break

11:00
MM 2201
Morbidity & Mortality Conference

12:00
Satellite Symposium

CF: Clinical Focus Session
TF: Technical Focus Session
VL: Video Learning Session
HL: Honorary Lecture
EM: ECIO meets
HDT: Hands-on Device Training
SED: Safe Sedation Training
BC: Basic Course
FP: Free Paper Session
MM: Morbidity and Mortality
Apply Now
and boost your career in IR

The EBIR is a globally recognised certification designed to give practising IRs the opportunity to certify their expertise and build their career.

Upcoming examinations:
• March 2020 – ECR
• September 2020 – CIRSE
• March 2021 – ECR

Submit your application online at www.cirse.org/ebir
Sunday, April 26

08:30-10:00

Clinical Focus Session

CF 101 Metastatic colorectal cancer  
Moderators: D. Arnold (Hamburg/DE), P.L. Pereira (Heilbronn/DE)

101.1 Patient selection for locoregional treatment on a molecular basis  
C.T. Sofocleous (New York, NY/US)

101.2 Patient selection for locoregional treatment: clinical selection  
D. Arnold (Hamburg/DE)

101.3 Update on ablation results in colorectal liver mets  
M.R. Meijerink (Amsterdam/NL)

101.4 Combined approach to extend curative treatment  
A. Denys (Lausanne/CH)

101.5 Intra-arterial therapies: where are we now?  
F. Orsi (Milan/IT)

101.6 Lung metastases local treatment  
T. de Baère (Villejuif/FR)

10:30-12:00

Clinical Focus Session

CF 201 Cancer immunotherapy: clinical results  
Moderators: J. Haanen (Amsterdam/NL), C. Ottensmeier (Southampton/UK)

201.1 Immunotherapy in 2020: clinical indications  
G. Curigliano (Milan/IT)

201.2 Checkpoint inhibitors in HCC, lung and renal tumours  
U. Martens (Heilbronn/DE)

201.3 Beyond checkpoint inhibitors  
V. Gambardella (Valencia/ES)

201.4 Pseudo-, oligo-, and hyperprogression: clinical impact  
S. Champiat (Villejuif/FR)

201.5 Resistance to systemic immunotherapy: how to overcome  
J. Haanen (Amsterdam/NL)

10:30-12:00

Technical Focus Session

TF 202 Image guidance: case-based discussion  
Moderators: X. Buy (Bordeaux/FR), A. Fohlen (Caen/FR)

201.1 How to enhance conspicuity for hardly visible tumours  
A. Hocquelet (Lausanne/CH)

201.2 How to confirm the ablation is complete  
F.T. Lee (Madison, WI/US)

201.3 Combined CT and angio systems over CBCT: pro  
B. Guiu (Montpellier/FR)

201.4 Combined CT and angio systems over CBCT: con  
M.J.L. van Strijen (Nieuwegein/NL)

201.5 Tumour feeder detection: software solutions and clinical results  
V. Tacher (Creteil/FR)

201.6 Does guidance improve results?  
R. Bale (Innsbruck/AT)

recommended for EBIR preparation
Sunday, April 26

10:30-12:00

**Hands-on Device Training**

**TA-HDT 1  Tumour ablation – Radiofrequency**
Coordinators: J.M. Abadal (Madrid/ES), F. Orsi (Milan/IT)

10:30-12:00

**Hands-on Training**

**SED 1  Safe sedation application during IR procedures (basic)**
Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)

13:00-14:30

**Satellite Symposia**

13:00-14:30

**Hands-on Training**

**SED 2  Safe sedation application during IR procedures (basic)**
Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)

15:00-16:30

**Clinical Focus Session**

**CF 401  Hepatocarcinoma: from classification to treatment**
Moderators: M. Fuchs (Munich/DE), R. Lencioni (Pisa/IT)

401.1 Critical view on HCC classification
M. Ronot (Clichy/FR)

401.2 Borderline in HCC nodules: the early stage
P.L. Pereira (Heilbronn/DE)

401.3 Borderline in HCC nodules: the intermediate stage
R. Golfieri (Bologna/IT)

401.4 Trials vs. reality: what is the role of radioembolisation?
E. Garin (Rennes/FR)

401.5 HCC and systemic treatment in 2020
B. Sangro (Pamplona/ES)

Round table discussion
15:00-16:30
**Clinical Focus Session**

**CF 402** Other organs ablation  
*Moderators: J. Garnon (Strasbourg/FR), to be announced*

402.1 Adrenal  
*R. L. Cazzato (Strasbourg/FR)*

402.2 Breast: local  
*J. Palussière (Bordeaux/FR)*

402.3 Pancreas: local  
*H. J. Scheffer (Amsterdam/NL)*

402.4 Lymph nodes  
*G. Tsoumakidou (Lausanne/CH)*

402.5 Thyroid cancer  
*R. Cervelli (Pisa/IT)*

402.6 Soft tissue tumour  
*T. K. Helmberger (Munich/DE)*

15:00-16:30
**Hands-on Device Training**

**TA-HDT 2** Tumour ablation – Radiofrequency  
*Coordinators: J. M. Abadal (Madrid/ES), F. Orsi (Milan/IT)*

15:00-16:30
**Hands-on Training**

**SED 3** Safe sedation application during IR procedures (advanced)  
*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*

17:00-18:30
**Clinical Focus Session**

**CF 501** HCC: patient management  
*Moderators: M. Ikeda (Tokyo/JP), K. Malagari (Athens/GR)*

501.1 Current status of biopsy in HCC  
*J. Bell (Manchester/UK)*

501.2 From bridging and downstaging to transplantation  
*to be announced*

501.3 The bleeding HCC tumour: management and outcomes  
*M. Burrel (Barcelona/ES)*

501.4 HCC with portal vein invasion  
*R. Salem (Chicago, IL/US)*

501.5 HCC in non-cirrhotic liver  
*H. Pinto Marques (Lisbon/PT)*

501.6 Combining locoregional treatment and immunotherapy in 2020  
*P. Reimer (Karlsruhe/DE)*

---

*recommended for EBIR preparation*
17:00-18:30

**Clinical Focus Session**

**CF 502**  
**Nuclear medicine and interventional oncology – present and future**  
*Moderators: H. Ilhan (Munich/DE), M.G.E.H. Lam (Utrecht/NL)*

- **502.1** New targets in nuclear medicine opportunities for IO  
  *N. Schaefer (Lausanne/CH)*

- **502.2** Intra-arterial PRRT liver metastases from NET  
  to be announced

- **502.3** Kidney and lung radioembolisation  
  *J. Ricke (Munich/DE)*

- **502.4** PET PSMA and prostate cancer  
  to be announced

- **502.5** Yttrium, Holmium, Radium, etc.  
  *M.G.E.H. Lam (Utrecht/NL)*

- **502.6** Lipiodol in nuclear medicine is back  
  *E. Garin (Rennes/FR)*

17:00-19:00

**Basic Course**

**BC 503**  
**GU primer and adrenal disease**  
*Moderator: R.F. Grasso (Rome/IT)*

- **503.1** Arterial and venous anatomy of the kidney and adrenal gland  
  *L. Tselikas (Paris/FR)*

- **503.2** Optimising renal embolisation after iatrogenic injury  
  *T. Bryant (Southampton/UK)*

- **503.3** Adrenal ablation: when and how?  
  *R.F. Grasso (Rome/IT)*

- **503.4** Urological bone metastases: when and how to treat?  
  *F. Deschamps (Villejuif/FR)*

- **503.5** Focal urological bone metastases: case for ablation versus SBRT  
  *A.N. Kurup (Rochester, MN/US)*

18:30-19:15

**Satellite Symposia**
Monday, April 27

08:00-08:20
Satellite Symposia

08:30-10:00
Clinical Focus Session
CF 801 Cholangiocarcinoma
Moderators: T.K. Helmberger (Munich/DE), P.L. Pereira (Heilbronn/DE)

801.1 Imaging of perihilar carcinoma
A. Guthrie (Leeds/UK)

801.2 Perihilar cholangiocarcinoma: staging and surgical results
G. Kazemier (Amsterdam/NL)

801.3 Endobiliary treatments of PCC: from light to waves
V. Válek (Brno/CZ)

801.4 Percutaneous ablative treatments of PCC and mass forming cholangiocarcinoma
K.P. van Lienden (Amsterdam/NL)

801.5 Systemic treatment for cholangiocarcinoma
J. Bridgewater (London/UK)

801.6 Intra-arterial treatments for cholangiocarcinoma
F. Wacker (Hannover/DE)

08:30-10:00
Clinical Focus Session
CF 802 IO 4 IO
Moderators: G. Adema (Nijmegen/NL), N. Goldberg (Jerusalem/IL)

802.1 Local delivery of immunotherapy: drugs candidates
S. Champiat (Villejuif/FR)

802.2 Local delivery of immunotherapy: routes
T. de Baère (Villejuif/FR)

802.3 Local delivery of immunotherapy: results
J. Brody (New York, NY/US)

802.4 Ablation and immunomodulation: the best scheme and technique
S. Haen (Tübingen/DE)

802.5 Intra-arterial treatments and immunomodulation: the best scheme and technique
R. Duran (Lausanne/CH)

802.6 Combining IO treatment and systemic immunotherapy: clinical results
A. Digklia (Lausanne/CH)

08:30-10:00
Hands-on Training
SED 4 Safe sedation application during IR procedures (basic)
Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)
10:30-11:30

**HL 901 Honorary Lecture**

Moderators: P. Chevallier (Nice/FR), A. Gangi (Strasbourg/FR)

*Laudation: E. Brountzos (Athens/GR)*

901.1 History of chemoembolisation of the liver: novelties and clinical practice – the evolution of research methodology

*K. Malagari (Athens/GR)*

10:30-12:00

**Hands-on Device Training**

TA-HDT 3 Tumour ablation – Microwave

Coordinators: S. Ilyas (London/UK), P.P. Rao (Colmar/FR)

10:30-12:00

**Hands-on Training**

SED 5 Safe sedation application during IR procedures (advanced)

Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)

11:30-12:00

**Free Paper Session**

FP 902 Free Papers 1

Moderators: P. Chevallier (Nice/FR), A. Gangi (Strasbourg/FR)

12:15-13:00

**ECIO meets**

EM 1001 ECIO meets JSIR

Moderators: Y. Arai (Tokyo/JP), A. Denys (Lausanne/CH)

1001.1 Technical innovation of TACE in Japan

*T. Tanaka (Kashiwa/JP)*

1001.2 RFA for lung metastasis

*K. Yamakado (Osaka/JP)*

1001.3 Challenges in clinical trials of palliative IO: Japanese perspective

*M. Sone (Tokyo/JP)*

13:00-14:30

**Satellite Symposia**

13:00-14:30

**Hands-on Training**

SED 6 Safe sedation application during IR procedures – (advanced, focus on propofol)

Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)
### Clinical Focus Session

**CF 1101**  
**Primary lung tumours**  
*Moderators: J. Palussière (Bordeaux/FR), to be announced*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1101.1</td>
<td>Biopsies of lung tumours</td>
<td>J.Y. Gaubert (Marseille/FR)</td>
</tr>
<tr>
<td>1101.2</td>
<td>Stage I surgery: sub lobar, VATS, robotics and results</td>
<td>to be announced</td>
</tr>
<tr>
<td>1101.3</td>
<td>Early-stage tumours: indications &amp; limitations of SBRT</td>
<td>S. Heymann (Strasbourg/FR)</td>
</tr>
<tr>
<td>1101.4</td>
<td>Early-stage tumours: results of thermal ablation</td>
<td>R.D. Suh (Los Angeles, CA/US)</td>
</tr>
<tr>
<td>1101.5</td>
<td>Oligometastatic lung cancer: optimal management</td>
<td>S.B. Solomon (New York, NY/US)</td>
</tr>
<tr>
<td>1101.6</td>
<td>New concepts in lung cancer</td>
<td>C. Ottensmeier (Southampton/UK)</td>
</tr>
</tbody>
</table>

### Clinical Focus Session

**CF 1102**  
**IO to optimise liver surgery**  
*Moderators: A. Denys (Lausanne/CH), J.-N. Vauthey (Houston, TX/US)*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1102.1</td>
<td>Liver failure after surgery: definition and risk factors</td>
<td>A. Iannelli (Nice/FR)</td>
</tr>
<tr>
<td>1102.2</td>
<td>How to better predict liver function: MR with primovist, CT volumetry, and Mbrofenin scintigraphy</td>
<td>M. Ronot (Clichy/FR)</td>
</tr>
<tr>
<td>1102.3</td>
<td>ALPPS: a critical review</td>
<td>J.-N. Vauthey (Houston, TX/US)</td>
</tr>
<tr>
<td>1102.4</td>
<td>Radioembolisation is the best way to promote liver growth</td>
<td>R. Salem (Chicago, IL/US)</td>
</tr>
<tr>
<td>1102.5</td>
<td>Portal vein embolisation: technical issues</td>
<td>J.H. Luz (Lisbon/PT)</td>
</tr>
<tr>
<td>1102.6</td>
<td>PVE: liver venous deprivation</td>
<td>B. Guiu (Montpellier/FR)</td>
</tr>
</tbody>
</table>

### Hands-on Device Training

**TA-HDT 4**  
**Tumour ablation – Microwave**  
*Coordinators: S. Ilyas (London/UK), P.P. Rao (Colmar/FR)*

*recommended for EBIR preparation*
17:00-18:30

**Clinical Focus Session**

**CF 1201 Robotics and AI**
*Moderators: L. Solbiati (Rozzano/IT), to be announced*

1201.1 Artificial intelligence in oncology
*to be announced*

1201.2 Artificial intelligence in interventional oncology
*J. Chapiro (New Haven, CT/US)*

1201.3 Augmented reality in IO
*F. Wacker (Hannover/DE)*

1201.4 Treatment planification
*A. King (Southampton/UK)*

1201.5 Robotics for ablation
*K. de Jong (Groningen/NL)*

1201.6 Robotics, AI, ...where is the future heading?
*B.J. Wood (Bethesda, MD/US)*

17:00-18:30

**Clinical Focus Session**

**CF 1202 MSK: curative treatment in oligometastatic bone disease**
*Moderators: M.R. Callstrom (Rochester, MN/US), A. Gangi (Strasbourg/FR)*

1202.1 Who is the ideal candidate for local treatment?
*M.R. Callstrom (Rochester, MN/US)*

1202.2 SBRT – results for complete local remission
*S. Heymann (Strasbourg/FR)*

1202.3 Ablation tools and how to use them
*J.W. Jennings (Saint Louis, MO/US)*

1202.4 Avoiding complications: tips and tricks
*R.L. Cazzato (Strasbourg/FR)*

1202.5 Results of ablation
*R.-T. Hoffmann (Dresden/DE)*

1202.6 Challenges in imaging follow-up: ablation vs. SBRT
*A.D. Kelekis (Athens/GR)*

17:00-19:00

**Basic Course**

**BC 1203 Renal cancer ablation**
*Moderator: D.J. Breen (Southampton/UK)*

1203.1 Epidemiology: when to treat and when not to treat?
*T.K. Nielsen (Aarhus/DK)*

1203.2 Renal cancer biopsy: when and how best done?
*T.M. Wah (Leeds/UK)*

1203.3 Renal cancer ablation: optimal technique
*D.J. Breen (Southampton/UK)*

1203.4 Avoiding and managing complications
*G.D. Schmit (Rochester, MN/US)*

1203.5 Understanding the current outcome data compared to surgery
*O. Graumann (Odense/DK)*

18:30-19:15

**Satellite Symposia**
Tuesday, April 28

08:00-08:20
Satellite Symposia

08:30-10:00
Clinical Focus Session

**CF 1501  Renal cancer ablation: moving forward**

*Moderators: A. Bex (Amsterdam/NL), D.J. Breen (Southampton/UK)*

- 1501.1 T1 renal disease: scope of the problem
  T.K. Nielsen (Aarhus/DK)
- 1501.2 How to manage renal cancer syndromes
  E. Woodward (Manchester/UK)
- 1501.3 Ablation and surgery: functional impact?
  O. Graumann (Odense/DK)
- 1501.4 Surgery for T1 renal tumours: current trends
  A. Bex (Amsterdam/NL)
- 1501.5 Optimising renal tumour ablation
  D.J. Breen (Southampton/UK)
- 1501.6 Renal tumour ablation: avoiding complications
  G.D. Schmit (Rochester, MN/US)

08:30-10:00
Clinical Focus Session

**CF 1502  Upcoming European research**

*Moderators: M.R. Meijerink (Amsterdam/NL), S.B. Solomon (New York, NY/US)*

- 1502.1 Intratumoral immunotherapy
  L. Tselikas (Villejuif/FR)
- 1502.2 Cryo priming in immunoresponse
  R. Duran (Lausanne/CH)
- 1502.3 Combining IRE and immunotherapy
  H.J. Scheffer (Amsterdam/NL)
- 1502.4 Serum and tumoral biomarkers can predict recurrence after HCC locoregional therapies
  R. Muglia (Rozzano/IT)
- 1502.5 Endothelial antibody capture – a potential strategy for innovative locoregional tumor diagnosis and treatment
  C.-M. Sommer (Heidelberg/DE)
- 1502.6 Direction of travel for IO research
  N. Goldberg (Jerusalem/IL)

---

*recommended for EBIR preparation*
10:30-12:00

**Clinical Focus Session**

**CF 1601 Challenges in IO**

*Moderators: G. Narayanan (Miami, FL/US), G.M. Varano (Milan/IT)*

- 1601.1 IO in pediatrics
  *A.M. Barnacle (London/UK)*

- 1601.2 Chemosaturation: FOCUS study results
  *B. Stedman (Southampton/UK)*

- 1601.3 Central liver tumours: we don’t need IRE
  *P. Chevallier (Nice/FR)*

- 1601.4 Central liver tumours: IRE is the solution
  *O. Seror (Bondy/FR)*

- 1601.5 Starting an MR-guided programme
  *A. King (Southampton/UK)*

- 1601.6 Brain tumours: IO solutions
  *G. Gahide (Montreal/CA)*

10:30-12:00

**Clinical Focus Session**

**CF 1602 Palliation in oncology**

*Moderators: J.K. Bell (Manchester/UK), T.J. Kroencke (Augsburg/DE)*

- 1602.1 Abdominal neurolysis: optimising results
  *D.K. Filippiadis (Athens/GR)*

- 1602.2 Improving nutrition in cancer patients
  *H.-U. Laasch (Manchester/UK)*

- 1602.3 Ascites in cancer patients
  *G. Maleux (Leuven/BE)*

- 1602.4 Bleeding complications after radiotherapy: how to manage
  *L. Tselikas (Villejuif/FR)*

- 1602.5 Palliation of carcinoid syndrome
  *J. Urbano (Madrid/ES)*

- 1602.6 Vascular complications after Whipple procedure
  *D. Poretti (Rozzano/IT)*

10:30-12:00

**Hands-on Device Training**

**TA-HDT 5 Tumour ablation – Cryo- and laser**

*Coordinators: A.H. Mahnken (Marburg/DE), G. Mauri (Milan/IT)*

13:00-14:30

**Satellite Symposia**
15:00-16:30

**Clinical Focus Session**

**CF 1801** MSK palliation: the pelvic bone  
Moderators: J.W. Jennings (St. Louis, MO/US), A.D. Kelekis (Athens/GR)

1801.1 Biomechanics and anatomy of the pelvic bone  
J. Garnon (Strasbourg/FR)

1801.2 Clinical and radiological evaluation  
S. Bauones (Riad/SA)

1801.3 Surgery: what is feasible and what is reasonable?  
M. Jayankura (Brussels/BE)

1801.4 Percutaneous cementoplasty  
A.N. Kurup (Rochester, MN/US)

1801.5 Percutaneous screw fixation  
F. Deschamps (Villejuif/FR)

1801.6 When and how to ablate  
D.K. Filippiadis (Athens/GR)

15:00-16:30

**Video Learning Session**

**VL 1802** How I do it  
Moderators: I. Bargellini (Pisa/IT), C.T. Sofocleous (New York, NY/US)

1802.1 Hepatic intra-arterial port  
Y. Arai (Tokyo/JP)

1802.2 MR-guided prostate interventions  
J.J. Fütterer (Nijmegen/NL)

1802.3 Organ protection and ablation  
R. Iezzi (Rome/IT)

1802.4 Liver venous deprivation: transjugular approach  
A. Hocquelet (Lausanne/CH)

1802.5 Chemosaturation  
G.M. Varano (Milan/IT)

1802.6 Pancreatic IRE  
G. Narayanan (Miami, FL/US)

15:00-16:30

**Hands-on Device Training**

**TA-HDT 6** Tumour ablation – Image guidance  
Coordinators: R. Bale (Innsbruck/AT), A. Hakimé (Villejuif/FR)

---

recommended for EBIR preparation
17:00-18:30

**Clinical Focus Session**

**CF 1901 Imaging and clinical follow-up**

*Moderators: C. Ayuso (Barcelona/ES), to be announced*

- 1901.1 Liver ablation
  - L. Crocetti (Pisa/IT)
- 1901.2 Liver chemoembolisation
  - E. Coimbra (Lisbon/PT)
- 1901.3 Liver radioembolisation
  - I. Bargellini (Pisa/IT)
- 1901.4 Kidney ablation
  - J. Correas (Paris/FR)
- 1901.5 Lung ablation and SBRT
  - R.D. Suh (Los Angeles, CA/US)
- 1901.6 Pancreas ablation
  - to be announced

17:00-18:30

**Free Paper Session**

**FP 1902 Free Papers 2**

17:00-19:00

**Basic Course**

**BC 1903 Prostate cancer**

* Moderator: J.J Fütterer (Nijmegen/NL)*

- 1903.1 Scope of the problem and where IO can help
  - T. Dudderidge (Southampton/UK)
- 1903.2 Prostate anatomy: relevance to ablation
  - R.L. Cazzato (Strasbourg/FR)
- 1903.3 Best ablation tools and image guidance
  - B.J. Wood (Bethesda, MD/US)
- 1903.4 The case for MR-targeted biopsy and focal ablation
  - S. Jenniskens (Nijmegen/NL)
- 1903.5 MR-guided prostate cryoablation: the way to go?
  - J.J Fütterer (Nijmegen/NL)

18:30-19:15

**Satellite Symposia**
Wednesday, April 29

08:30-10:00

Technical Focus Session

TF 2101  Tips and tricks: case-based discussion

2101.1 Lymphatic leaks
F. Douane (Nantes/FR)

2101.2 Combined TACE and ablation
T.F. Jakobs (Munich/DE)

2101.3 Nerve protection in the pelvis
A.N. Kurup (Rochester, MN/US)

2101.4 Liver: complex biliary procedures
D.W. de Boo (New Lambton Heights/AU)

2101.5 Portal vein occlusion after abdominal surgery
J. Bell (Manchester/UK)

2101.6 Extrahepatic feeders for TACE
S.J. Park (Incheon/KR)

08:30-10:00

Clinical Focus Session

CF 2102  Different ways of killing cancer – and why we need all of them
Moderators: A. Adam (London/UK), L.M. Kenny (Brisbane/AU)

2102.1 Thermal ablation: RFA, MWA and HIFU – their advantages and limitations
N. Goldberg (Jerusalem/IL)

2102.2 Photons (fractionated radiotherapy and SABR): selective death and total destruction
L.M. Kenny (Brisbane/AU)

2102.3 Cryotherapy: precise but dangerous if not used carefully
A. Gangi (Strasbourg/FR)

2102.4 Particle therapy: will it redefine imaging-guided treatment?
J. Doyen (Nice/FR)

Panel discussion

10:30-12:00

MM 2201  Morbidity & Mortality
Coordinators: T. Bilhim (Lisbon/PT), D. Poretti (Rozzano/IT)
Basic Course
Genitourinary

This format aims to offer a basic course series for beginners, focusing on a different organ each year. At ECIO 2020, the topic of this six-hour course will be Genitourinary and will feature three distinct sessions, structured by the content included in the new European Curriculum and Syllabus for IR. It will allow a limited number of participants to receive a comprehensive overview of the topic, from diagnostics, imaging, treatment and follow-up.

Sunday, April 26
BC 503 – GU primer and adrenal disease  17:00-19:00
Moderator: R.F. Grasso (Rome/IT)

503.1 Arterial and venous anatomy of the kidney and adrenal gland
L. Tselikas (Paris/FR)

503.2 Optimising renal embolisation after iatrogenic injury
T. Bryant (Southampton/UK)

503.3 Adrenal ablation: when and how?
R.F. Grasso (Rome/IT)

503.4 Urological bone metastases: when and how to treat?
F. Deschamps (Villejuif/FR)

503.5 Focal urological bone metastases: case for ablation versus SBRT
A.N. Kurup (Rochester, MN/US)

Monday, April 27
BC 1203 – Renal cancer ablation  17:00-19:00
Moderator: D.J. Breen (Southampton/UK)

1203.1 Epidemiology: when to treat and when not to treat?
T.K. Nielsen (Aarhus/DK)

1203.2 Renal cancer biopsy: when and how best done?
T.M. Wah (Leeds/UK)

1203.3 Renal cancer ablation: optimal technique
D.J. Breen (Southampton/UK)

1203.4 Avoiding and managing complications
G.D. Schmit (Rochester, MN/US)

1203.5 Understanding the current outcome data compared to surgery
O. Graumann (Odense/DK)

Tuesday, April 28
BC 1903 – Prostate cancer  17:00-19:00
Moderator: J.J. Fütterer (Nijmegen/NL)

1903.1 Scope of the problem and where IO can help
T. Dudderidge (Southampton/UK)

1903.2 Prostate anatomy: relevance to ablation
R.L. Cazzatto (Strasbourg/FR)

1903.3 Best ablation tools and image guidance
B.J. Wood (Bethesda/US)

1903.4 The case for MR-targeted biopsy and focal ablation
S. Jenniskens (Nijmegen/NL)

1903.5 MR-guided prostate cryoablation: the way to go?
J.J. Fütterer (Nijmegen/NL)

How to participate:
Participation is free of charge, but places are limited and will be allocated on a first come, first served basis.
Hands-on Device Training

Tumour ablation

Percutaneous ablation plays an increasingly fundamental role for the loco-regional treatment of cancer. Ablation technologies and equipment for live image guidance are developing quickly.

This Hands-on Device Training (HDT) aims to provide an overview of available technologies. Separate sessions will look at radiofrequency ablation, microwave ablation, cryoablation and laser ablation, as well as image guidance.

After a short kick-off presentation by the HDT coordinators, participants will have the opportunity to learn about the specifics, as well as the safe and effective use of the available technology in a hands-on setting.

Each HDT will feature a round-table discussion with the coordinators at the end of each session allowing participants to ask questions and give feedback.

Sunday, April 26
TA-HDT 1 – Radiofrequency 10:30-12:00
TA-HDT 2 – Radiofrequency 15:00-16:30

Coordinators: J.M. Abadal (Madrid/ES), F. Orsi (Milan/IT)

Monday, April 27
TA-HDT 3 – Microwave 10:30-12:00
TA-HDT 4 – Microwave 15:00-16:30

Coordinators: S. Ilyas (London/UK), P.P. Rao (Strasbourg/FR)

Tuesday, April 28
TA-HDT 5 – Cryoablation and laser ablation 10:30-12:00

Coordinators: A.H. Mahnken (Marburg/DE), G. Mauri (Milan/IT)

TA-HDT 6 – Image guidance 15:00-16:30

Coordinators: R. Bale (Innsbruck/AT), A. Hakimé (Villejuif/FR)

How to participate:

Participation is free of charge, but places are limited and will be allocated on a first come, first served basis.

As all these sessions offer practical medical training, participation is for qualified medical professionals only.
Safe sedation application during IR procedures

This practical workshop will give participants the opportunity to perform procedural sedation in a simulated environment and learn about the most common respiratory complications, as well as which instruments are available to make these interventions safer.

These training sessions are carried out on a full-scale patient simulator with capnography, BIS monitoring and TIVA/TCI pumps. Participants will perform these therapies under the supervision of AQAI’s experienced trainers.

In the advanced sessions, participants can additionally perform sedations for high-risk patients, e.g. those with hypertonia, severe cardiac diseases or pulmonary diseases like COPD. Participants in these sessions should visit a basic session first or should have substantial experience in procedural sedation.

One of the available sessions will focus on the use of propofol and will provide training for sedation using this drug for repeated boluses, during continuous infusion techniques and during the TCI (target controlled infusion) technique. The workshop will specifically explore the possible safety issues associated with propofol. To participate in this session, attendees should have already attended a basic session and should have some basic knowledge about the special pharmacology of propofol. Please note that as the use of propofol by non-anaesthesiologists is strictly forbidden in some countries, this may be a limitation for some interested participants.

Learning objectives

• To apply procedural sedation using various approaches
• To identify complications and challenges during procedural sedation
• To assess the value of various monitoring technologies
• To recognise the added value of capnography during sedation
• To select appropriate sedation techniques in high-risk patients
• To identify limitations and situations where the help of an anaesthesiologist is mandatory

Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)

Sunday, April 26
SED 1 – Basic 10:30-12:00
SED 2 – Basic 13:00-14:30
SED 3 – Advanced 15:00-16:30

Monday, April 27
SED 4 – Basic 08:30-10:00
SED 5 – Advanced 10:30-12:00
SED 6 – Advanced (focus on propofol) 13:00-14:30

How to participate:

Participation is free of charge, but places are limited and will be allocated on a first come, first served basis.

As all these sessions offer practical medical training, participation is for qualified medical professionals only.
Registration

Online registration (secured payment) for ECIO 2020 is available at www.ecio.org.

Please note that your registration must be submitted and full payment needs to be received by the respective registration deadlines. Otherwise the respective next higher fee will be due. Furthermore, please be advised that incomplete registrations (not containing full name, email and address) cannot be processed.

Registration Fees

<table>
<thead>
<tr>
<th>Early – until January 16, 2020 (23:59 CET)</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congress Registration</td>
<td>610</td>
</tr>
<tr>
<td>CIRSE Member</td>
<td>410</td>
</tr>
<tr>
<td>Resident</td>
<td>320</td>
</tr>
<tr>
<td>Resident Member</td>
<td>270</td>
</tr>
<tr>
<td>Nurse / Radiographer*</td>
<td>270</td>
</tr>
<tr>
<td>Undergraduate Medical Student**</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Middle – until March 5, 2020 (23:59 CET)</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congress Registration</td>
<td>810</td>
</tr>
<tr>
<td>CIRSE Member</td>
<td>570</td>
</tr>
<tr>
<td>Resident</td>
<td>455</td>
</tr>
<tr>
<td>Resident Member</td>
<td>405</td>
</tr>
<tr>
<td>Nurse / Radiographer*</td>
<td>405</td>
</tr>
<tr>
<td>Undergraduate Medical Student**</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Late – until April 24, 2020</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congress Registration</td>
<td>880</td>
</tr>
<tr>
<td>CIRSE Member</td>
<td>770</td>
</tr>
<tr>
<td>Resident</td>
<td>490</td>
</tr>
<tr>
<td>Resident Member</td>
<td>440</td>
</tr>
<tr>
<td>Nurse / Radiographer*</td>
<td>440</td>
</tr>
<tr>
<td>Undergraduate Medical Student**</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Onsite – from April 25, 2020</th>
<th>€</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congress Registration</td>
<td>980</td>
</tr>
<tr>
<td>CIRSE Member</td>
<td>870</td>
</tr>
<tr>
<td>Resident</td>
<td>590</td>
</tr>
<tr>
<td>Resident Member</td>
<td>540</td>
</tr>
<tr>
<td>Nurse / Radiographer*</td>
<td>540</td>
</tr>
<tr>
<td>Undergraduate Medical Student**</td>
<td>0</td>
</tr>
</tbody>
</table>

* To be accompanied by a certificate, signed by the head of department.

** To be accompanied by a confirmation of student status at the time of congress, a one-page CV and a copy of a valid photo ID.

Registration fee inclusive 21% VAT in France.

Cancellation of congress registration

CIRSE GmbH offers all pre-registered participants the possibility to take out cancellation insurance with its partner “Europäische Reiseversicherung”. The insurance can only be booked during and until finalisation of the online registration process. The refund of the participant’s registration fee due to cancellation of the registration or the change of registration category is only possible with a valid insurance. All requests must be made to “Europäische Reiseversicherung” directly. Refunds will be given according to the terms and conditions of the “Europäische Reiseversicherung”. CIRSE GmbH shall not be responsible for any refunds of registration fees.

Name changes will be handled as a cancellation and new registration.

Additional information

All ECIO 2020 registrants will be able to print out an invoice of registration using their personal login details at www.ecio.org.

Invoices will be issued by: CIRSE Congress Innovation Research GmbH, Neutorgasse 9/6, 1010 Vienna, Austria

CME Credit Allowance

An application will be made to the EACCME® for CME accreditation of ECIO 2020.

Important Addresses

Congress Venue
Palais des Congrès Nice Acropolis
1 Esplanade Kennedy
06364 Nice Cedex 4, France

Organising Secretariat
CIRSE Central Office
Neutorgasse 9
1010 Vienna, Austria
Phone: +43 1 904 2003
Fax: +43 1 904 2003 30
Email: info@cirse.org
Web: www.ecio.org

Email Contacts

For general enquiries about the ECIO 2020 meeting, please send an email to info@cirse.org.

In the case of queries concerning registration for the ECIO 2020 meeting, please send an email to registration@ecio.org.

For information about the scientific programme of ECIO 2020, please send an email to scientific@cirse.org.

Reduced CIRSE Member registration is only available for members of CIRSE (Cardiovascular and Interventional Radiological Society of Europe) in good standing.

Method of payment
Registration fees are to be paid in Euros (€) by:
Bank transfer or Credit Card (Visa or Mastercard)
Accommodation

In cooperation with our travel partner Kuoni Congress, CIRSE has secured a great number of hotel rooms in Nice for the benefit of our congress participants.

For further information about the official ECIO hotels and room bookings, please refer to www.ecio.org.

If you have any questions, please do not hesitate to contact Kuoni Congress:

Contact: Viera Bacova & Karin Amstler
ecio2020@kuoni-congress.com
+420 296 301 204

---

List of hotels

<table>
<thead>
<tr>
<th>Hotel name</th>
<th>Category</th>
<th>Single room (€)</th>
<th>Double room (€)</th>
<th>WALKING</th>
<th>PUBLIC</th>
<th>TAXI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Aston La Scala Hotel</td>
<td>4*</td>
<td>181,20</td>
<td>198,40</td>
<td>15 min</td>
<td>5 min</td>
<td></td>
</tr>
<tr>
<td>2 Beau Rivage Nice Hotel</td>
<td>4*</td>
<td>181,20</td>
<td>198,40</td>
<td>15 min</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>3 Ellington Nice Centre</td>
<td>4*</td>
<td>162,20</td>
<td>174,40</td>
<td>10 min</td>
<td>5 min</td>
<td></td>
</tr>
<tr>
<td>4 Hipark by Adagio</td>
<td>4*</td>
<td>113,20</td>
<td>124,40</td>
<td>5 min</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5 Holiday Inn Nice</td>
<td>4*</td>
<td>182,20</td>
<td>199,40</td>
<td>20 min</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>6 Hyatt Regency Nice</td>
<td>5*</td>
<td>253,00</td>
<td>276,00</td>
<td>20 min</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>7 Le Meridien Nice</td>
<td>4*</td>
<td>237,20</td>
<td>254,40</td>
<td>20 min</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>8 Masséna Best Western Plus Nice</td>
<td>4*</td>
<td>193,20</td>
<td>205,40</td>
<td>15 min</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>9 NH Nice</td>
<td>4*</td>
<td>177,20</td>
<td>190,90</td>
<td>5 min</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10 Nice Riviera</td>
<td>4*</td>
<td>147,20</td>
<td>169,40</td>
<td>15 min</td>
<td>10 min</td>
<td></td>
</tr>
<tr>
<td>11 Novotel Nice Centre Vieux</td>
<td>4*</td>
<td>171,20</td>
<td>192,40</td>
<td>5 min</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

All room rates are in Euro (EUR) inclusive of breakfast, VAT and city tax based on 2020. Please note, that all taxes and service charges are subject to change according to the official legislation.
Registered participants traveling to ECIO 2020 are invited to take advantage of a discount of up to 10% when booking their flight with Lufthansa Group Partner Airlines!

Lufthansa Group Partner Airlines offer a comprehensive global route network linking major cities around the world. To make a reservation, please visit www.ecio.org/attend/flights-discounts/ and enter the following access code: ATZQXBJ

Special rates are offered on flights operated by Austrian, Lufthansa, Swiss, Brussels Airlines and Eurowings and are valid from April 19 until May 6, 2020. Some flights to Nice with Air Canada or United Airlines flight numbers are also eligible for the discount.

We look forward to welcoming you to Nice!
CVIR: your journal for IO research

Publish in CVIR to reach an international audience!

- more than 8,000 subscribers
- official organ of over 20 national IR societies
- a dedicated IO section in each monthly issue

Recent highlights include a special section on oncology in the September 2019 issue, edited by Prof. Thierry de Baère

www.cvironline.org
The European Conference on Interventional Oncology is organised by CIRSE (Cardiovascular and Interventional Radiological Society of Europe).

The official congress website is: www.ecio.org

To contact the CIRSE Central Office or members of the committee please write to info@cirse.org.

ECIO 2020 Preliminary Programme
In case of any enquiries or comments, please contact us at info@cirse.org

© Cardiovascular and Interventional Radiological Society of Europe / 2019

CIRSE does not accept responsibility for errors or misprints.

Cover: Place Massena and Fountain du Soleil at Dawn
Nice, France
© www.shutterstock.com

GraphX by LOOP ENTERPRISES media
www.loop-enterprises.com